Don't expect Eli Lilly to pump up its sales force as new diabetes drugs make their debuts over the next three years. As Lilly Diabetes President Enrique Conterno tells Bloomberg, the company ($LLY) plans to lean on its broad product portfolio to grow sales, rather than sending out legions of reps to push new drugs brand-by-brand. "I don't think the market is responsive today to putting more and more sales people focused on brands," Conterno told the news service. "We start with the patient and think of all the therapies we could have for him." Report